Serum lipid profiles in patients receiving endocrine treatment for breast cancer—the results from the Celecoxib Anti-Aromatase Neoadjuvant (CAAN) Trial
References (18)
- et al.
Cyclooxygenase regulates angiogenesis induced by colon cancer cells
Cell
(1998) - et al.
Correlation of aromatase and cyclooxygenase gene expression in human breast cancer specimens
Cancer Lett
(1999) - et al.
Expression of aromatase protein and messenger ribonucleotide acid in tumor epithelial cells and evidence of functional significance of locally produced estrogen in human breast cancers
Endocrinology
(1996) Anti-aromatase agents in the treatment and prevention of breast cancer
Cancer Control
(2002)- et al.
Celecoxib: a specific COX-2 inhibitor with anticancer properties
Cancer Control
(2002) - et al.
Hormonal receptor determination of 1052 Chinese breast cancers
J Surg Oncol
(2002) - et al.
Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors
Cancer Res
(2000) - et al.
Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor
Cancer Res
(2000) - et al.
Nonsteroidal anti-inflammatory drugs and breast cancer
Epidemiology
(1996)
Cited by (17)
Exploration of structural requirements for azole chemicals towards human aromatase CYP19A1 activity: Classification modeling, structure-activity relationships and read-across study
2022, Toxicology in VitroCitation Excerpt :CYP19A1 is mostly present in the peripheral tissues such as fat and muscle, and especially in the breast and ovarian cells of females (Honda et al., 1994; Mahendroo et al., 1991; Simpson et al., 1993; Stocco, 2012; Leshin et al., 1981; Mahendroo et al., 1993). Any disturbance in the aromatase activity induces imbalance of estrogen levels in tissues which further disrupts estrogen mediated physiological responses, leading to endocrine disruption (Blakemore and Naftolin, 2016; Chow et al., 2005; Njar and Brodie, 2015; Aromatase Assay (Human Recombinant) Standard Evaluation Procedure (SEP), 2011; Adhikari et al., 2017a, 2017b; Jha et al., 2015). Many chemical species including pesticides, antifungal and antibacterial substances can influence the CYP19A1 activity in three different ways; i) compounds that can disturb normal functioning of the enzyme by procatalysis are categorized as agonists; ii) some chemical species inhibit the activity of aromatase enzyme for the natural substrate (androgen) and are known as antagonists (or aromatase inhibitors); (iii) Some may also act as allosteric inhibitors (Zhang et al., 2020; Ghosh et al., 2016a, 2016b).
Design, synthesis and structure-activity relationship study of novel pyrazole-based heterocycles as potential antitumor agents
2010, European Journal of Medicinal ChemistryCitation Excerpt :On the other hand, several authors have reported the inhibitory effects of celecoxib on breast cancer [2–6], recurrent malignant glioma [7], advanced non-small cell lung cancer [8–10], refractory multiple myeloma [11], advanced colorectal cancer [12] and advanced pancreatic cancer [13]. It was proved that celecoxib exerts its antitumor action via inhibition of aromatase, an enzyme complex consisting of a cytochrome P-450 hemoprotein and a flavoprotein, which converts C-19 androgens, such as testosterone and androstenedione, to C-18 estrogen such as estradiol and estrone [14–17]. Therefore, it is useful in controlling the progression of tumors with estrogen receptors; i.e. breast and ovarian tumors.
Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer
2008, Journal of Steroid Biochemistry and Molecular BiologyEmerging roles of low-density lipoprotein in the development and treatment of breast cancer
2019, Lipids in Health and Disease